Autism is a vexed problem today. Overall, there is a high frequency of birth children (1:80 – 1:150) with late diagnosed autism spectrum disorders (ASD) and this trend is getting progressively stronger. The causes for the currently increased frequency of ASD and the pathogenesis of ASD are not fully understood yet. One of the most likely mechanisms inducing ASD may be a maternal immune imprinting. This phenomenon is based on transplacental translocation of maternal antibodies of IgG class and, as a consequence, on the epigenetic “tuning” of immune system of the fetus and child. This mechanism provides development of child’s anti-infection resistance before meeting with microorganisms, but it can be also a cause of inborn pathology including the ASD appearance. The quantitative changes in maternal blood serum autoantibodies depend on a specific microbial population, or are induced by environmental chemical pollutants in association with some individual features of the maternal metabolism. These immune changes are adaptive in most cases for the maternal organism, but can be pathogenic for the fetus in some cases. We discuss in the present paper the possibilities to predict the risk from abnormal development of nervous system in fetus and early diagnosis of ASD in high-risk group of children.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Rossignol DA Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation inflammation oxidative stress mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry 2012;17:389-401.
2. Popov NT Madjirova NP Minkov IN Vachev TI. Micro RNA HSA-486-3P gene expression profiling in the whole blood of patients with autism. Biotechnology & Biotechnological Equipment 2012;26(6):3385-8.
3. Anney R Klei L Pinto D et al. Individual common variants exert weak effects on the risk for autism spectrum disorderspi. Hum Mol Genet 2012;21:4781-92.
4. Khoroshko VK. The living organism reaction to administration of the nervous tissue [dissertation]. Moscow: Moscow Univ. Publishing; 1912.
5. Semenov SV Popova NN. Nervous and mental diseases from point of view of the brain’s immuno-pathology. Moscow: Meditsina Publishers; 1969.
6. Poletaev AB Morozov SG Kovaliov IE. Regulatory metasystem (the neuro-immuno-endocrine system for regulation of homeostasis). Moscow: Medicina; 2002.
7. Camara EG Danao TC. The brain and the immune system: A psychosomatic network. Psychosomatics 1989;30:140-6.
8. Ferenchk M Stvrtinov V. Is the immune system our sixth sense? Relation between the immune and neu-roendocrine systems. Bratisl Lek Listy 1997;98:187-98.
9. Morley JE Kay NE Solomon GF Plotnikoff NP. Neuropeptides: conductors of the immune orchestra. Life Sci 1987;41:527-44.
10. Pianchi M Ferrario P Clavenna A Panerai AE. Interleukin-6 affects scopolamine-induced amnesia but not brain amino acid levels in mice. Neuro Report 1997;8:1775-8.
11. Poletaev AB. Immunophysiology and immunopa-thology. Moscow: MIA; 2008.
12. Poletaev AB. Physiological Immunology. Moscow: MIKLOSH Publishers; 2010.
13. Poletaev A. The main principles of adaptive immune system function: self-recognition self-interaction and self-maintenance. In: Poletaev AB editor. Physiologic Autoimmunity and Preventive Medicine. Sharjah Oak Park Bussum: Bentham Science Publishers; 2013:3-20.
14. Landor M. Maternal-fetal transfer of immunoglobu-lins. Ann Allergy Asthma Immunol 1995;74:279-83.
15. Basten A. Basis and mechanism of self-tolerance. In: Rose NR Mackay IR editors. The autoimmune diseases. San Diego London: Acad Press 1998:9-27.
16. Lemke H Radu IT Ahmad T Lange H. Benefits and burden of the maternally-mediated immunological imprinting In: Poletaev AB Dabilov AN editors. Immunophysiology: natural autoimmunity in physiology and pathology. Proceedings of 2nd Moscow International Conference Moscow; 2008:58-64.
17. Lemke H Lange H. Is there a maternally induced immunological imprinting a la Konrad Lorenz? Scand J Immunol 1999;50:348-54.
18. Lacroix-Desmazes S Kaveri S Mouthon L Ayouba A Malanchere E Coutinho A Kazatchkine MD. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Meth 1998; 216:117-37.
19. Grabar P. About Autoantibodies. In: Ado AD editor. Problems of reactivity in pathology. Moscow: Meditsina; 1968:35-52.
20. Kovaliov IE Polevaya OY. Biochemical grounds of immunity against low-molecular chemical compounds. Moscow: Nauka Publishers; 1985.
21. Poletaev AB Abrosimova AA Sokolov MA et al. Dialectics and implications of natural neuro-tropic autoantibodies in neurological disease and rehabilitation. Clin And Developmental Immunol 2004;11:151-6.
22. Bieber AJ Warrington A Pease LR Rodriguez M. Humoral autoimmunity as a mediator of CNS repair. Trends Neurosci 2001;24(11 Suppl):S39-44.
23. Shoenfeld Y Carp HJ Molina V et al. Autoantibodies and prediction of reproductive failure. Am J Reprod Immunol 2006;56:337-44.
24. McKenzie JM Zakarija M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH-receptor antibodies. Thyroid 1992;2:155-9.
25. Lim M-S Liu Z Drolet BA Diaz LA. Cutaneous autoimmune diseases. In: Rose NR Mackay IR editors. The autoimmune diseases. San Diego London: Acad Press 1998:623-36.
26. Budykina TS. Autoantibodies against insulin insulin receptors and NGF in pathogenesis of diabetic fetopathy [dissertation]. Moscow: University of defence 1998.
27. Khlystova ZS. Ontogenetic formation of the immune system in humans. Moscow: Medicina Publishers; 1987.
28. Kluchnikov SO Poletaev AB Budykina TS Gener-alova GA. New immunobiotechnology approaches in perinatology and pediatrics. In: Demin VF Kluch-nikov SO eds. Lectures in pediatrics. Moscow: RGMU Publishers;2001:243-67.
29. Patterson PH. Maternal infection: window on neu-roimmune interactions in fetal brain development and mental illness. Current Opinion in Neurobiol 2002;15:115-18.
30. Pistola V. Production of cytokines by human B-cells in health and disease. Immunol Today 1997; 18:343-9.
31. Wu Y Liu Y. Viral induction of co-stimulatory activity on antigen-presenting cells bypasses the need for CD4+ T-cell responses. Current Biol 1994;4:499-505.
32. Ghosh A Michalon A Lindemann L et al. Drug discovery for autism spectrum disorder: challenges and opportunities. Nat Rev Drug Discov 2013;12:777-90.
33. Weintraub K. The prevalence puzzle: autism counts. Nature 2011;479:22-4.
34. Meroni PL De Angelis V Tedesco F. Future trends. In: Shoenfeld Y Gershwin ME Meroni PL editors. Autoantibodies. Elsevier B.V. 2007:823-6.
35. Poletaev A. Autoantibodies: serum content or profiles? In: Poletaev AB editor. Physiologic autoimmunity and preventive medicine. Sharjah Oak Park Bussum: Bentham Science Publishers; 2013:199-207.